Two experts address the impact of disease course on therapy, general instructions for patients, individualizing treatment, thymectomy, newer selective immunotherapies and more.
Myasthenia Gravis: Frequently Asked Questions About Evaluation and Diagnosis
Two experts address the clinical hallmarks of this chronic autoimmune neuromuscular disorder as well as risk factors and the role of antibody testing and electrodiagnostic tests.
What Are the Treatment Options for Myasthenia Gravis if First-Line Agents Fail?
For the 5% to 20% of patients with generalized myasthenia gravis who have suboptimal response to pyridostigmine or substantial adverse effects, it may be time to consider immunosuppressive therapy. This short review offers guidance on choice of agents.
Myasthenia Gravis: Practice and Research Updates (Podcast)
Progress in our ability to diagnose and treat this autoimmune disorder has been encouraging — and all signs suggest that it will continue.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
5 Things That Struck Me at the AAN’s 2018 Annual Meeting
Dr. Robert Bermel reflects on some presentations at the recent AAN meeting that could make 2018 a very consequential year in neurology.